Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Care Reform's 340B Provisions Could Impact Oncology Near-Term

Executive Summary

Companies with oncology products should take a look at the health reform law's provisions on the 340B drug discount program when assessing the new law's early impact, a review by the consulting firm KantarHealth suggests

You may also be interested in...

Higher Medicaid Rebates Expected To Boost Private Payer Discounts Too

The recently signed health care reform law will enable private payers to seek deeper discounts on drugs than they often can now, because the law, in effect, creates a lower "best price" floor for drugs by increasing the base Medicaid drug rebate to 23.1 percent

On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era

The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry

Final Health Reform Bill Looks Positive For Pharma Firms

It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts